Neurocrine Biosciences (NBIX) Return on Assets [ROA] (2009 - 2026)
Neurocrine Biosciences' Return on Assets [ROA] was 12.79% in Q3 2026, up 2.29 percentage points from 10.50% a year earlier but down 0.96 percentage points from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Return on Assets [ROA] (2009 - 2026) Analysis & Trends
For FY2025, Return on Assets [ROA] at Neurocrine Biosciences came in at 11.46%, up 1.67 percentage points from FY2024.
- Return on Assets [ROA] has now increased for four consecutive years, though with a five-year change of -15.33 percentage points (FY2020 to FY2025).
- In earlier years, Return on Assets [ROA] was 9.79% in FY2024 (+0.91 pp), 8.89% in FY2023 (+1.93 pp), 6.96% in FY2022 (+2.25 pp) and 4.71% in FY2021 (-22.08 pp).
- Quarterly Return on Assets [ROA] has moved between 0.59% (Q2 2022) and 14.02% (Q1 2026) over five years.
- Compared with a year earlier, Return on Assets [ROA] has increased for four straight quarters, with an average year-over-year change of +1.35 percentage points over the last eight quarters.
- The best year-over-year quarter for Return on Assets [ROA] over five years was Q1 2024 (a gain of 8.29 percentage points); the worst was Q4 2021 (a drop of 20.78 percentage points).
- Per Business Quant data, NBIX's Return on Assets [ROA] in the three quarters before Q3 2026 was 13.75% (Q2 2026), 14.02% (Q1 2026) and 10.76% (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 19.00% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 8.08% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 7.32% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 1.87% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 9.36% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 9.80% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | -7.67% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 2.00% |
| 10 | Neurocrine Biosciences | 17.13 Bn | 13.21 Bn | 1.10 Bn | 12.63% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 12.63% |
| Jun 30, 2026 | 13.60% |
| Mar 31, 2026 | 13.84% |
| Dec 31, 2025 | 10.92% |
| Sep 30, 2025 | 10.46% |
| Jun 30, 2025 | 9.46% |
| Mar 31, 2025 | 8.41% |
| Dec 31, 2024 | 9.38% |
| Sep 30, 2024 | 11.76% |
| Jun 30, 2024 | 10.12% |
| Mar 31, 2024 | 11.18% |
| Dec 31, 2023 | 8.68% |
| Sep 30, 2023 | 7.45% |
| Jun 30, 2023 | 7.54% |
| Mar 31, 2023 | 2.99% |
| Dec 31, 2022 | 6.57% |
| Sep 30, 2022 | 2.11% |
| Jun 30, 2022 | -0.03% |
| Mar 31, 2022 | 2.90% |
| Dec 31, 2021 | 4.21% |
API Access
Neurocrine Biosciences Return on Assets [ROA] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-assets-[roa]", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();